|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B显示文摘AIM:To evaluate the durability in hepatitis B e antigen (HBeAg) positive chronic hepatitis B patients who discontinued antiviral treatment. METHODS:A total of 48 HBeAg positive chronic hepatitis B patients who were administered nucleoside analogues and maintained virological response for ≥ 6 mo [hepatitis B virus (HBV) DNA < 300 copies/mL and HBeAg seroconversion] before cessation of treatment were enrolled between February 2007 and January 2010. The criteria for the cessation of the antiviral treatment were defined as follows:(1) achievement of virological response; and (2) duration of consolidation therapy (≥ 6 mo). After treatment cessation, the patients were followed up at 3-6 mo intervals. The primary endpoint was serologic and virologic recurrence rates after withdrawal of antiviral treatment. Serologic recurrence was defined as reappearance of HBeAg positivity after HBeAg seroconversion. Virologic recurrence was defined as an increase in HBV-DNA level > 104 copies/mL after HBeAg seroconversion with previously undetectable HBV-DNA level. RESULTS:During the median follow-up period of 18.2 mo (range:5.1-47.5 mo) after cessation of antiviral treatment, the cumulative serological recurrence rate was 15 % at 12 mo. The median duration between the cessation of antiviral treatment and serologic recurrence was 7.2 mo (range:1.2-10.9 mo). Of the 48 patients with HBeAg positive chronic hepatitis, 20 (41.6%) showed virological recurrence. The cumulative virologic recurrence rates at 12 mo after discontinuing the antiviral agent were 41%. The median duration between off-treatment and virologic recurrence was 7.6 mo (range:4.3-27.1 mo). The mean age of the virological recurrence group was older than that of the non-recurrence group (46.7 ± 12.1 years vs 38.8 ± 12.7 years, respectively; P = 0.022). Age (> 40 years) and the duration of consolidation treatment (≥ 15 mo) were significant predictive factors for offtreatment durability in the multivariate analysis [P = 0.049, relative risk (RR) 0.31, 95% CI (0.096-0.998) and P = 0.005, RR 11.29, 95% CI (2.054-65.12), respectively]. Patients with age (≤ 40 years) who received consolidation treatment (≥ 15 mo) significantly showed durability in HBeAg positive chronic hepatitis B patients (P = 0.014). These results suggest that additional treatment for more than 15 mo after HBeAg seroconversion in patients who are ≤ 40 years old may be beneficial in providing a sustained virological response. CONCLUSION:Our data suggest that HBeAg seroconversion is an imperfect end point in antiviral treatment. Long-term consolidation treatment (≥ 15 mo) in younger patients is important for producing better prognosis in HBeAg positive chronic hepatitis B. | Myeong Jun Song Do Seon Song Hee Yeon Kim Sun Hong Yoo Si Hyun Bae Jong Young Choi Seung Kew Yoon Yong-Han Paik June Sung Lee Hyun Woong Lee Hyung Joon Kim | 2012 | World Journal of Gastroenterology2012，18，43： | 7 |
| 2 | Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma显示文摘AIM:To investigate the efficacy and safety of transarterial chemoembolization(TACE)-based multimodal treatment in patients with large hepatocellular carcinoma(HCC).METHODS:A total of 146 consecutive patients were included in the analysis,and their medical records and radiological data were reviewed retrospectively.RESULTS:In total,119 patients received TACE-based multi-modal treatments,and the remaining 27 received conservative management.Overall survival(P<0.001)and objective tumor response(P=0.003)were significantly better in the treatment group than in the conservative group.After subgroup analysis,survival benefits were observed not only in the multi-modal treatment group compared with the TACE-only group(P=0.002)but also in the surgical treatment group compared with the loco-regional treatment-only group(P<0.001).Multivariate analysis identified tumor stage(P<0.001)and tumor type(P=0.009)as two independent pre-treatment factors for survival.After adjusting for significant pre-treatment prognostic factors,objective response(P<0.001),surgical treatment(P=0.009),and multi-modal treatment(P=0.002)were identified as independent post-treatment prognostic factors.CONCLUSION:TACE-based multi-modal treatments were safe and more beneficial than conservative management.Salvage surgery after successful downstaging resultedin long-term survival in patients with large,unresectable HCC. | Do Seon Song Soon Woo Nam Si Hyun Bae Jin Dong Kim Jeong Won Jang Myeong Jun Song Sung Won Lee Hee Yeon Kim Young Joon Lee Ho Jong Chun Young Kyoung You Jong Young Choi Seung Kew Yoon | 2015 | World Journal of Gastroenterology2015，21，8： | 7 |
| 3 | Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis显示文摘AIM: To evaluate the prognostic factors and efficacy of hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. METHODS: Fifty hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) were treated using hepatic arterial infusion chemotherapy (HAIC) via a subcutaneously implanted port. The epirubicin-cisplatin-5-fluorouracil (ECF) chemotherapeutic regimen consisted of 35 mg/m 2 epirubicin on day 1, 60 mg/m 2 cisplatin for 2 h on day 2, and 500 mg/m 2 5-fluorouracil for 5 h on days 1-3. The treatments were repeated every 3 or 4 wk. RESULTS: Three (6%) of the 50 patients achieved a complete response (CR), 13 (26%) showed partial responses (PR), and 22 (44%) had stable disease (SD).The median survival and time to progression were 7 and 2 mo, respectively. After 2 cycles of HAIC, CR was achieved in 1 patient (2%), PR in 10 patients (20%) and SD in 26 patients (52%). Significant pre-treatment prognostic factors were a tumor volume of < 400 cm 3 (P = 0.01) and normal levels of protein induced by vitamin K absence or antagonist (PIVKA)-Ⅱ (P = 0.022). After 2 cycles of treatment, disease control (CR + PR + SD) (P = 0.001), PVTT response (P = 0.003) and α-fetoprotein reduction of over 50% (P = 0.02) were independent factors for survival. Objective response (CR + PR), disease control, PVTT response, and combination therapy during the HAIC were also significant prognostic factors. Adverse events were tolerable and successfully managed. CONCLUSION: HAIC may be an effective treatment modality for advanced HCC with PVTT in patients with tumors < 400 cm 3 and good prognostic factors. | Do Seon Song Si Hyun Bae Myeong Jun Song Sung Won Lee Hee Yeon Kim Young Joon Lee Jung Suk Oh Ho Jong Chun Hae Giu Lee Jong Young Choi Seung Kew Yoon | 2013 | World Journal of Gastroenterology2013，19，29： | 5 |
| 4 | Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats显示文摘 | Kim do Y Chung SI Ro SW | 2013 | Apoptosis2013，18，12： | 1 |
| 5 | Ganglioneuroma of the uterine cervix--a case report显示文摘 | Do SI Kim GY Ki KD | | 0，，： | 1 |
| 6 | The Hepatitis B virus - X protein activates a phosphatidylinositol 3 - kinase - dependent sur- vival signaling cascade 显示文摘 | Lee YI Kang - Park S Do SI | 2001 | J Biol Chem2001，276，16： | 1 |
| 7 | Salvage chemotherapy for pretreated gastric cancer:a randomized phase Ⅲ trial comparing chemotherapy plus best supportive care with best supportive care alone显示文摘 | Kang JH Lee SI Lim do H | | 0，，13： | 1 |
| 8 | Akt protein kinase enhance human telomerase activity through phospherylation of telomerase reverse transcriptase subunit 显示文摘 | Kang SS Kwon T Do SI | 1999 | J Biol Chem1999，274，13： | 1 |
| 9 | Granular cell tumour onlarynx显示文摘 | Park JH Do NY Cho SI | 2010 | Clin Exp Otorhinolaryngol2010，3，1： | 1 |
| 10 | Expandable metallic stent placement in patients with benign esophageal strictures: results of long-term follow-up显示文摘 | Song HY Park SI Do YS | 1997 | Radiology1997，203，： | 1 |
| 11 | Diagnostic and Prog- nostic Relevance of MMP-11 Expression in the Stro- mal Fibroblast-Like Cells Adjacent to Invasive Ductal Carcinoma of the Breast显示文摘 | Min KW Kim DH Do SI | 2013 | Ann Surg Oncol2013，20，3： | 1 |
| 12 | Electrochemical properties of LiFePO4 prepared via hydrothermal route显示文摘 | Kaoru Do Shohei K Keisuke Si | 2007 | Journal of Power Sources2007，165，： | 1 |
| 13 | The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade显示文摘 | Lee YI Kang-Park S Do SI | 2001 | J Biol Chem2001，276，16： | 1 |
| 14 | Psychosoeial Aspects of Ache Vulgaris: A Community-based Study with Korean Adolescents 显示文摘 | Do JE Cho SM In SI | 2009 | Ann Dermatol2009，21，2： | 1 |
| 15 | Production of low ash coal by thermal extraction with N-methyl-2-pyrrolidinone显示文摘 | Sang Do Kim Kwang Jae Woo Soon Kwan Jeong Young Jun Rhim Si Hyun Lee | 2008 | Korean Journal of Chemical Engineering2008，，4： | 1 |
| 16 | Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit 显示文摘 | Kang SS Kwon T Kwon DY Do SI | 1999 | J Biol Chem1999，274，13： | 1 |
| 17 | The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma显示文摘 | Do SI Jung WW Kim HS | 2009 | Int J Oncol2009，34，3： | 1 |
| 18 | Associations between theexpression of mucins ( MUC1,MUC2, MUC5AC,and MUC6 )and clinicopathologic parameters of human breast ductalcarcinomas显示文摘 | Do SI Kim K Kim DH | 2013 | J Breast Cancer2013，16，2： | 1 |
| 19 | Clinicopathologic correlation of beclin-1 expression in pancreatic ductal adenocarcinoma 显示文摘 | Kim HS Lee SH Do SI | 2011 | Pathol Res Pract2011，207，4： | 1 |
| 20 | Diagnostic anti prognostic relevance of Cullinl expression in invasive ductal carcinoma of the breast 显示文摘 | Min KW Kim DH Do SI | 2012 | Clin Pathol2012，6，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员